These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 39055715)
21. Systemic and local human papillomavirus 16-specific T-cell immunity in patients with head and neck cancer. Heusinkveld M; Goedemans R; Briet RJ; Gelderblom H; Nortier JW; Gorter A; Smit VT; Langeveld AP; Jansen JC; van der Burg SH Int J Cancer; 2012 Jul; 131(2):E74-85. PubMed ID: 22020783 [TBL] [Abstract][Full Text] [Related]
22. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas. Succaria F; Kvistborg P; Stein JE; Engle EL; McMiller TL; Rooper LM; Thompson E; Berger AE; van den Brekel M; Zuur CL; Haanen J; Topalian SL; Taube JM Cancer Immunol Immunother; 2021 May; 70(5):1227-1237. PubMed ID: 33125511 [TBL] [Abstract][Full Text] [Related]
23. Intratumoral delivery of an HPV vaccine elicits a broad anti-tumor immune response that translates into a potent anti-tumor effect in a preclinical murine HPV model. Ishida E; Lee J; Campbell JS; Chakravarty PD; Katori Y; Ogawa T; Johnson L; Mukhopadhyay A; Faquin WC; Lin DT; Wirth LJ; Pierce RH; Pai SI Cancer Immunol Immunother; 2019 Aug; 68(8):1273-1286. PubMed ID: 31243491 [TBL] [Abstract][Full Text] [Related]
24. Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma. Mito I; Takahashi H; Kawabata-Iwakawa R; Ida S; Tada H; Chikamatsu K Sci Rep; 2021 Aug; 11(1):16134. PubMed ID: 34373557 [TBL] [Abstract][Full Text] [Related]
25. Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy. Hanoteau A; Newton JM; Krupar R; Huang C; Liu HC; Gaspero A; Gartrell RD; Saenger YM; Hart TD; Santegoets SJ; Laoui D; Spanos C; Parikh F; Jayaraman P; Zhang B; Van der Burg SH; Van Ginderachter JA; Melief CJM; Sikora AG J Immunother Cancer; 2019 Jan; 7(1):10. PubMed ID: 30646957 [TBL] [Abstract][Full Text] [Related]
26. A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors. Wieking BG; Vermeer DW; Spanos WC; Lee KM; Vermeer P; Lee WT; Xu Y; Gabitzsch ES; Balcaitis S; Balint JP; Jones FR; Lee JH Cancer Gene Ther; 2012 Oct; 19(10):667-74. PubMed ID: 22918471 [TBL] [Abstract][Full Text] [Related]
27. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma. Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843 [TBL] [Abstract][Full Text] [Related]
28. Immunological protection against HPV16 E7-expressing human esophageal cancer cell challenge by a novel HPV16-E6/E7 fusion protein based-vaccine in a Hu-PBL-SCID mouse model. Lu Y; Zhang Z; Liu Q; Liu B; Song X; Wang M; Zhao X; Zhao Q Biol Pharm Bull; 2007 Jan; 30(1):150-6. PubMed ID: 17202676 [TBL] [Abstract][Full Text] [Related]
29. Human Papilloma Virus Specific Immunogenicity and Dysfunction of CD8 Krishna S; Ulrich P; Wilson E; Parikh F; Narang P; Yang S; Read AK; Kim-Schulze S; Park JG; Posner M; Wilson Sayres MA; Sikora A; Anderson KS Cancer Res; 2018 Nov; 78(21):6159-6170. PubMed ID: 30154146 [TBL] [Abstract][Full Text] [Related]
30. Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy. Pogorzelski M; Ting S; Gauler TC; Breitenbuecher F; Vossebein I; Hoffarth S; Markowetz J; Lang S; Bergmann C; Brandau S; Jawad JA; Schmid KW; Schuler M; Kasper S Cell Death Dis; 2014 Feb; 5(2):e1091. PubMed ID: 24577089 [TBL] [Abstract][Full Text] [Related]
31. PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas. Sanchez-Canteli M; Granda-Díaz R; Del Rio-Ibisate N; Allonca E; López-Alvarez F; Agorreta J; Garmendia I; Montuenga LM; García-Pedrero JM; Rodrigo JP Cancer Immunol Immunother; 2020 Oct; 69(10):2089-2100. PubMed ID: 32448984 [TBL] [Abstract][Full Text] [Related]
32. CD244 represents a new therapeutic target in head and neck squamous cell carcinoma. Agresta L; Lehn M; Lampe K; Cantrell R; Hennies C; Szabo S; Wise-Draper T; Conforti L; Hoebe K; Janssen EM J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217758 [TBL] [Abstract][Full Text] [Related]
33. Induction of CD4-independent E7-specific CD8+ memory response by heat shock fusion protein. Liu H; Wu BH; Rowse GJ; Emtage PC Clin Vaccine Immunol; 2007 Aug; 14(8):1013-23. PubMed ID: 17596433 [TBL] [Abstract][Full Text] [Related]
34. Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8 Hladíková K; Koucký V; Bouček J; Laco J; Grega M; Hodek M; Zábrodský M; Vošmik M; Rozkošová K; Vošmiková H; Čelakovský P; Chrobok V; Ryška A; Špíšek R; Fialová A J Immunother Cancer; 2019 Oct; 7(1):261. PubMed ID: 31623665 [TBL] [Abstract][Full Text] [Related]
35. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Badoual C; Hans S; Merillon N; Van Ryswick C; Ravel P; Benhamouda N; Levionnois E; Nizard M; Si-Mohamed A; Besnier N; Gey A; Rotem-Yehudar R; Pere H; Tran T; Guerin CL; Chauvat A; Dransart E; Alanio C; Albert S; Barry B; Sandoval F; Quintin-Colonna F; Bruneval P; Fridman WH; Lemoine FM; Oudard S; Johannes L; Olive D; Brasnu D; Tartour E Cancer Res; 2013 Jan; 73(1):128-38. PubMed ID: 23135914 [TBL] [Abstract][Full Text] [Related]
36. Characterization and Differentiation of the Tumor Microenvironment (TME) of Orthotopic and Subcutaneously Grown Head and Neck Squamous Cell Carcinoma (HNSCC) in Immunocompetent Mice. Brand M; Laban S; Theodoraki MN; Doescher J; Hoffmann TK; Schuler PJ; Brunner C Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33383676 [TBL] [Abstract][Full Text] [Related]
37. Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV Brand TM; Hartmann S; Bhola NE; Peyser ND; Li H; Zeng Y; Isaacson Wechsler E; Ranall MV; Bandyopadhyay S; Duvvuri U; LaVallee TM; Jordan RCK; Johnson DE; Grandis JR Clin Cancer Res; 2017 Jun; 23(12):3072-3083. PubMed ID: 27986750 [No Abstract] [Full Text] [Related]
38. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines. Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711 [TBL] [Abstract][Full Text] [Related]
39. Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV Galliverti G; Wullschleger S; Tichet M; Murugan D; Zangger N; Horton W; Korman AJ; Coussens LM; Swartz MA; Hanahan D Cancer Immunol Res; 2020 Jan; 8(1):131-145. PubMed ID: 31771984 [TBL] [Abstract][Full Text] [Related]
40. Mucosal HPV E6/E7 Peptide Vaccination in Combination with Immune Checkpoint Modulation Induces Regression of HPV Dorta-Estremera S; Chin RL; Sierra G; Nicholas C; Yanamandra AV; Nookala SMK; Yang G; Singh S; Curran MA; Sastry KJ Cancer Res; 2018 Sep; 78(18):5327-5339. PubMed ID: 30054333 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]